Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Vos, Alinda G ^a   Idris, Nikmah S ^a,b   Barth, Roos E ^a   Klipstein Grobusch, Kerstin ^a   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CARDIOVASCULAR DISEASE; CAROTID ARTERY; COMPLICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INTIMA; METABOLISM; PATHOLOGY; PROGNOSIS;

BIOMARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; HIV INFECTIONS; HUMANS; INFLAMMATION; PROGNOSIS; TUNICA INTIMA;

EID: 84973600574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147484     Document Type: Review

References (71)

1. Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JA. Immune activation and collateral damage in AIDS pathogenesis. Front Immunol 2013 Sep 26; 4:298. doi: 10.3389/fimmu. 2013.00298 PMID: 24133492
2. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008 Aug 15; 48(5):590-598. doi: 10.1097/QAI. 0b013e31817efb54 PMID: 18645512
3. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006 Sep; 43(1):27-34. PMID: 16878047
4. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010 Jun 19; 24(10):1537-1548. doi: 10.1097/QAD. 0b013e32833a0918 PMID: 20453631
5. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013 Mar 27; 27(6):973-979. doi: 10.1097/QAD.0b013e32835cae9c PMID: 23698063
6. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009 Dec 1; 54(23):2129-2138. PMID: 19942084
7. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011 Nov 7; 17(11):1410-1422. doi: 10.1038/nm.2538 PMID: 22064431
8. Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis 2012 Jun; 205 Suppl 3:S355-61. doi: 10.1093/infdis/jis195 PMID: 22577208
9. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7(9):e44454. doi: 10.1371/journal. pone.0044454 PMID: 22970224
10. Kaplan RC, Landay AL, Hodis HN, Gange SJ, Norris PJ, Young M, et al. Pmc3400505; Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012 Aug 1; 60:359-368. doi: 10.1097/QAI.0b013e31825b03be PMID: 22592585
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009 Jul 21; 339:b2700. doi: 10.1136/bmj.b2700 PMID: 19622552
12. Field N, Cohen T, Struelens MJ, Palm D, Cookson B, Glynn JR, et al. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infect Dis 2014 Apr; 14(4):341-352. doi: 10.1016/S1473-3099(13)70324-4 PMID: 24631223
13. Nordell AD, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD. Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation. J Am Heart Assoc 2014;3.
14. Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004 Oct 12; 110(15):2204-2209. PMID: 15466648
15. Joven J, Coll B, Tous M, Ferre N, Alonso-Villaverde C, Parra S, et al. The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis. Clin Chim Acta 2006 Jun; 368:114-119. PMID: 16445900
16. Coll B, Parra S, Alonso-Villaverde C, de Groot E, Aragones G, Montero M, et al. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine 2006 Apr; 34:51-55. PMID: 16697654
17. Parra S, Coll B, Aragones G, Marsillach J, Beltran R, Rull A, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med 2010 Apr; 11:225-231. doi: 10.1111/j.1468-1293.2009.00766.x PMID: 19845792
18. Longenecker CT, Jiang Y, Orringer CE, Gilkeson RC, Debanne S, Funderburg NT, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014 Apr 24; 28:969-977. doi: 10.1097/QAD.0000000000000158 PMID: 24691204
19. Hileman CO, Carman TL, Longenecker CT, Labbato DE, Storer NJ, White CA, et al. Rate and predictors of carotid artery intima media thickness progression in antiretroviral-naive HIV-infected and uninfected adults: a 48-week matched prospective cohort study. Antivir Ther (Lond) 2013; 18:921-929.
20. Hileman CO, Longenecker CT, Carman TL, McComsey GA. C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy. J Acquir Immune Defic Syndr 2014 Mar 1; 65:340-344. doi: 10.1097/QAI.0000000000000063 PMID: 24220288
21. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Pmc3475633; Biomarkers of microbial trans-location and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012 Nov 15; 206:1558-1567. doi: 10.1093/infdis/jis545 PMID: 23066162
22. Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. Pmc3653400; Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study. AIDS Res Hum Retroviruses 2013 Jun; 29:938-948. doi: 10.1089/AID.2012.0305 PMID: 23351153
23. Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007 May 31; 21(9): 1137-1145. PMID: 17502724
24. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006 Nov 28; 20:2275-2283. PMID: 17117013
25. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Pmc2691772; Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009 Jun 1; 23:1059-1067. doi: 10.1097/QAD.0b013e32832b514b PMID: 19390417
26. Hsue PY, Deeks SG, Hunt PW. Pmc3349295; Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012 Jun; 205 Suppl 3:S375-82. doi: 10.1093/infdis/jis200 PMID: 22577211
27. Mangili A, Gerrior J, Tang AM, O'Leary DH, Polak JK, Schaefer EJ, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006 Dec 1; 43(11):1482-1489. PMID: 17083026
28. Mangili A, Jacobson DL, Gerrior J, Polak JF, Gorbach SL, Wanke CA. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 2007 May 15; 44(10):1368-1374. PMID: 17443477
29. Mangili A, Ahmad R, Wolfert RL, Kuvin J, Polak JF, Karas RH, et al. Pmc3935500; Lipoproteinassociated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients. Clin Infect Dis 2014 Mar; 58:893-900. doi: 10.1093/cid/cit815 PMID: 24336757
30. Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, et al. Pmc3487373; Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc 2012 Apr;1.
31. Longenecker C, Funderburg N, Jiang Y, Debanne S, Storer N, Labbato D, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV medicine 2013; 14:385-390. doi: 10.1111/hiv.12013 PMID: 23332012
32. Baker JV, Henry WK, Patel P, Bush TJ, Conley LJ, Mack WJ, et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis 2011 Oct; 53(8): 826-835. doi: 10.1093/cid/cir497 PMID: 21860012
33. Tungsiripat M, El-Bejjani D, Rizk N, Dogra V, O'Riordan M, Ross A, et al. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses 2011; 27:295-302. doi: 10.1089/aid.2010.0187 PMID: 20969457
34. Falcao Mda C, Zirpoli JC, Albuquerque VM, Markman Filho B, Araujo NA, Falcao CA, et al. Association of biomarkers with atherosclerosis and risk for coronary artery disease in patients with HIV. Arq Bras Cardiol 2012 Nov; 99:971-978. PMID: 23080223
35. Badiou S, Thiebaut R, Aurillac-Lavignolle V, Dabis F, Laporte F, Cristol JP, et al. Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients. J Infect 2008 Jul; 57:47-54. doi: 10.1016/j.jinf.2008.05.007 PMID: 18554723
36. Bonilla H, McShannic J, Goldberg E, Chua D, Conner R, Fiorentino M, et al. Impact of human immunodeficiency virus infection on measures of cardiovascular disease in long-term nonprogressors. Infectious Diseases in Clinical Practice 2013; 21:177-180.
37. Freitas P, Carvalho D, Santos AC, Madureira AJ, Martinez E, Pereira J, et al. Carotid intima media thickness is associated with body fat abnormalities in HIV-infected patients. BMC Infect Dis 2014 Jun 23; 14:348. doi: 10.1186/1471-2334-14-348 PMID: 24958511
38. Jeong SJ, Kim CO, Song YG, Baek JH, Kim SB, Jin SJ, et al. Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy. Atherosclerosis 2011 Dec; 219:778-783. doi: 10.1016/j. atherosclerosis.2011.08.003 PMID: 21872861
39. Masia M, Robledano C, Ortiz de IT, Antequera P, Lopez N, Gutierrez F. Pmc3662719; Increased carotid intima-media thickness associated with antibody responses to varicella-zoster virus and cytomegalovirus in HIV-infected patients. PLoS One 2013; 8:e64327. doi: 10.1371/journal.pone.0064327 PMID: 23717597
40. Merlini E, Luzi K, Suardi E, Barassi A, Cerrone M, Martinez JS, et al. Pmc3459872; T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One 2012; 7:e46073. doi: 10.1371/journal.pone.0046073 PMID: 23029393
41. Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M, et al. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS 2013 Jan 28; 27:381-389. doi: 10.1097/QAD.0b013e32835abcc9 PMID: 23079800
42. Portilla J, Moreno-Perez O, Serna-Candel C, Escoin C, Alfayate R, Reus S, et al. Pmc4021989; Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV. J Int AIDS Soc 2014; 17:18945. doi: 10.7448/IAS.17.1.18945 PMID: 24836607
43. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Pmc3895473; Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009 Oct 1; 49:1119-1127. doi: 10. 1086/605578 PMID: 19712036
44. Ross Eckard A, Longenecker C, Jiang Y, Debanne S, Labbato D, Storer N, et al. Lipoproteinassociated phospholipase A and cardiovascular disease risk in HIV infection. HIV Med 2014 Mar 20.
45. Sankatsing RR, Wit FW, Vogel M, de Groot E, Brinkman K, Rockstroh JK, et al. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors. Atherosclerosis 2009 Feb; 202(2):589-595. doi: 10.1016/j. atherosclerosis.2008.05.028 PMID: 18599064
46. Ssinabulya I, Kayima J, Longenecker C, Luwedde M, Semitala F, Kambugu A, et al. Pmc3938501; Sub-clinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. PLoS One 2014; 9:e89537. doi: 10.1371/journal.pone.0089537 PMID: 24586854
47. Stein J, Brown T, Ribaudo H, Chen Y, Yan M, Lauer-Brodell E, et al. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2013; 27:929-937. doi: 10.1097/QAD.0b013e32835ce27e PMID: 23196938
48. van Wijk JP, de Koning EJ, Cabezas MC, Joven J, op't Roodt J, Rabelink TJ, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006 Mar 21; 47:1117-1123. PMID: 16545639
49. Westhorpe CL, Maisa A, Spelman T, Hoy JF, Dewar EM, Karapanagiotidis S, et al. Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. Immunol Cell Biol 2014 Feb; 92:133-138. doi: 10.1038/icb.2013.84 PMID: 24296810
50. Barbour JD, Jalbert EC, Chow DC, Gangcuangco LMA, Norris PJ, Keating SM, et al. Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive anti-retroviral therapy. Atherosclerosis 2014; 232:52-58. doi: 10.1016/j.atherosclerosis.2013. 10.021 PMID: 24401216
51. De Luca A, de GD, Colafigli M, Cozzi-Lepri A, De Curtis A, Gori A, et al. Pmc3846422; The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis 2013; 13:414. doi: 10.1186/1471-2334-13-414 PMID: 24004495
52. Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, et al. Pmc2884071; Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010 Jun 19; 24:1509-1517. doi: 10.1097/QAD.0b013e32833ad914 PMID: 20505494
53. Knudsen A, Moller HJ, Katzenstein TL, Gerstoft J, Obel N, Kronborg G, et al. Pmc3663777; Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study. BMC Infect Dis 2013; 13:230. doi: 10.1186/1471-2334-13-230 PMID: 23692821
54. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. J Infect Dis 2014 May 1.
55. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Pmc3071127; Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011 Mar 15; 203:780-790. doi: 10.1093/infdis/jiq118 PMID: 21252259
56. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009 Jul 1; 51(3):268-273. doi: 10.1097/QAI. 0b013e3181a9992c PMID: 19387353
57. Kaplan RC, Landay AL, Hodis HN, Gange SJ, Norris PJ, Young M, et al. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012 Aug 1; 60(4):359-368. doi: 10.1097/QAI.0b013e31825b03be PMID: 22592585
58. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011 Mar 15; 203(6):780-790. doi: 10. 1093/infdis/jiq118 PMID: 21252259
59. Baker J, Neuhaus J, Duprez D, Cooper D, Hoy J, Kuller L, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 2011; 25:2133-2142. doi: 10.1097/QAD.0b013e32834be088 PMID: 21857489
60. Pirro M, Stingeni L, Vaudo G, Mannarino MR, Ministrini S, Vonella M, et al. Systemic inflammation and imbalance between endothelial injury and repair in patients with psoriasis are associated with preclinical atherosclerosis. Eur J Prev Cardiol 2014 Jun 6.
61. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005 Aug; 52(8): 2293-2299. PMID: 16052597
62. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004 Apr 1; 350(14):1387-1397. PMID: 15070788
63. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003 Jan 28; 107(3):363-369. PMID: 12551853
64. Willeit P, Thompson A, Aspelund T, Rumley A, Eiriksdottir G, Lowe G, et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS One 2013; 8(2):e55175. doi: 10.1371/journal.pone.0055175 PMID: 23408959
65. Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS One 2012; 7(4):e34218. doi: 10.1371/journal.pone.0034218 PMID: 22514624
66. Su D, Li Z, Li X, Chen Y, Zhang Y, Ding D, et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm 2013; 2013:726178. doi: 10. 1155/2013/726178 PMID: 23818744
67. Willeit P, Thompson SG, Agewall S, Bergstrom G, Bickel H, Catapano AL, et al. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev Cardiol 2014 Nov 21.
68. Baldassarre D, De Jong A, Amato M, Werba JP, Castelnuovo S, Frigerio B, et al. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis. Ann Med 2008; 40(1): 21-44. PMID: 17934910
69. Shah S, Ma Y, Scherzer R, Huhn G, French AL, Plankey M, et al. Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels. AIDS. 2015 Jul 7; 29(11): 1325-33. doi: 10.1097/QAD.0000000000000654 PMID: 25870985
70. th of November 2015
71. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009 Jul; 158(1):1-7. doi: 10.1016/j.ahj.2009.04.019 PMID: 19540385